Neil Kumar, BridgeBio CEO (Jeff Rumans for Endpoints News)

Af­ter De­cem­ber tri­al fail, Bridge­Bio has good news from PhII for LGMD2i drug

Bridge­Bio Phar­ma was in need of some good news. It got some from its Phase II tri­al of a drug for limb-gir­dle mus­cu­lar dy­s­tro­phy type 2i, and will now talk to drug reg­u­la­tors to talk about po­ten­tial paths to ap­proval.

The bio­phar­ma is pre­sent­ing the re­sults at this week’s Mus­cu­lar Dy­s­tro­phy As­so­ci­a­tion An­nu­al Meet­ing in Nashville. Bridge­Bio be­lieves that the re­sults show that BBP-418, al­so known as ribitol, can in­crease gly­co­sy­la­tion of αDG and dri­ve func­tion­al im­prove­ments and re­duce CK, which is a key mark­er of mus­cle break­down. It’s big news for a dis­ease in which there are no ap­proved treat­ment op­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.